10/02/23 1:00 AMOTC : RHHBY conferencesGenentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSDGenentech, a member of the Roche Group, will present new data for Ocrevus ® and investigational Bruton’ s tyrosine kinase inhibitor fenebrutinib for multiple sclerosis, and Enspryng ® for neuromyelitis optica spectrum disorder. In total, Genentech will be presenting 36 abstracts at the 9th Joint ECTRIMS-ACTRIMS Meeting from October 11-13, 2023.RHEA-AInegative
10/02/23 1:00 AMOTC : RHHBY conferencesRoche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD Late-breaking results from Phase III trial of OCREVUS ( ocrelizumab ) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented 10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progressionRHEA-AIneutral
09/07/23 7:00 AMOTC : RHHBY clinical trialRoche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular diseaseZilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placebo Study met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six months Zilebesiran demonstratedRHEA-AIneutral
09/06/23 1:00 AMOTC : RHHBY clinical trialFDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood ConditionGenentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has accepted the company’ s Biologics License Application for crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, for the treatment of paroxysmal nocturnal hemoglobinuria. The acceptance was based on results from the pivotal Phase III...RHEA-AIneutral
09/05/23 1:00 AMOTC, NYSE : RHHBY, ROG, RHHBF Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcareRoche– The Economist Impact report, Advancing the Frontier of Health and Technology Integration: The 2023 Digital Health Barometer, commissioned by Roche Diagnostics, examines the digital health environment in and across ten diverse countries from advanced economies to emerging markets: Australia, Brazil, France,...RHEA-AIpositive
09/01/23 1:00 AMOTC : RHHBY clinical trialGenentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung CancerGenentech, a member of the Roche Group, announced today that the Phase III ALINA study evaluating Alecensa ®, compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival at a prespecified interim analysis. Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant...RHEA-AIneutral
09/01/23 1:00 AMOTC : RHHBY clinical trialRoche’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancerALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced setting About half of people with NSCLC experience disease recurrence following surgery, despiteRHEA-AIvery positive
08/29/23 5:00 AMOTC : RHHBY Roche’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutesTecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenous Tecentriq , including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatment Administered under the skin within approx. seven minutes,RHEA-AIvery positive
08/29/23 1:00 AMOTC : RHHBY European Commission approves Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)Evrysdi available to treat people of all ages with SMA in the European Union, including babies from birth 1 Approval is based on interim data from ongoing RAINBOWFISH trial showing majority of Evrysdi -treated babies were able to stand and walk within timeframes typical of healthy babies by 12RHEA-AIneutral
08/23/23 1:43 AMOTC : RHHBY clinical trialGenentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung CancerGenentech, a member of the Roche Group, has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq ® versus Tecentriq alone as an initial treatment for people with PD-L1-high locally advanced or metastatic...RHEA-AInegative